Clinical Trial With Donor Modified Immune Cells in Living Donor Kidney Transplantation

Launched by TOLEROGENIXX GMBH · May 3, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called MIC to see how effective and safe it is for patients receiving a kidney transplant from a living donor. In this trial, 63 pairs of kidney donors and recipients will be involved. The recipients will be randomly placed into one of two groups: one group will receive the MIC treatment along with reduced doses of standard medications to prevent their body from rejecting the new kidney, while the other group will only receive the standard medications without the MIC treatment. The goal is to determine if the MIC treatment can help improve the transplant outcomes.

To participate in this trial, kidney recipients must be adults aged 18 to 69 who are preparing for their first kidney transplant from a living donor. They should have severe kidney disease and meet specific medical criteria. Participants will receive the treatment, followed by a 12-month follow-up period where their health and the effectiveness of the treatment will be closely monitored. Overall, this trial aims to explore a new way to enhance the success of kidney transplants while keeping patients safe.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Donors:
• • 1. Age ≥18 years and able to consent
• • 2. Ability to understand the nature and scope of the clinical trial
• • 3. Written consent form given prior to any trial-related procedures (including PBMC donation)
• Patients:
• • 1. Patient with CKD in stage 5 (e.g., estimated glomerular filtration rate \[eGFR\] \<15 mL/min and/or on renal replacement therapy), who are in preparation for kidney transplantation from a live donor
• • 2. Age ≥18 years, \<70 years
• • 3. ABO-blood group identical or compatible with donor
• • 4. First kidney transplantation
• • 5. Complement dependent cytotoxicity (CDC)-panel reactive antibodies \<20%
• • 6. No detection of a donor-specific HLA-antibody in the Luminex-Assay (cutoff: mean fluorescence intensity \[MFI\] ≤1,000)
• • 7. Negative CDC crossmatch with the donor
• • 8. Negative PCR test result for severe acute respiratory syndrome coronavirus-2 (SARSCoV-2) at Screening
• • 9. Patient's living donor gave written consent for trial participation
• • 10. Ability to understand the nature and scope of the clinical trial
• • 11. Written informed consent given prior to any trial-related procedures
• 12. Female patients of childbearing potential must:
• • 1. have a negative pregnancy test (blood) at Screening.
• • 2. either commit to true abstinence from heterosexual contact or agree to use, and be able to comply with, 2 highly effective measures of contraception control (failure rate less than 1% per year when used consistently and correctly) without interruption, during the trial participation. Patients who discontinue mycophenolic acid derivate during the trial participation can switch to 1 highly effective contraceptive method 6 weeks after the end of mycophenolic acid derivative treatment. Reliable methods for this trial are: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device, intrauterine hormone releasing system, bilateral tubal occlusion, sexual abstinence or vasectomized sexual partner. Abstinence from heterosexual contact is only accepted as true abstinence: when this is in line with the preferred and usual lifestyle of the patient. (Periodic abstinence \[e.g., calendar, ovulation, symptothermal, post-ovulation methods and withdrawal\] is not an acceptable method of contraception.) Postmenopausal (no menses for at least 1 year without alternative medical cause) or surgically sterile female patients (tubal ligation, hysterectomy or bilateral oophorectomy) may be enrolled.
• • 3. agree to abstain from breast feeding during the trial participation.
• • 13. Male patients must practice true abstinence or agree to use a condom during sexual contact with a pregnant woman or a woman of childbearing potential during the trial participation and for at least 90 days after the end of mycophenolic acid derivative treatment, even if he has undergone a successful vasectomy.
• Exclusion Criteria:
• Donors:
• • 1. Pregnant or breastfeeding
• • 2. Participation in an interventional clinical trial within 30 days prior to Screening or in observation period of a competing study
• • 3. Severe psychiatric disease
• • 4. Severe cardiovascular diseases (i.e., heart insufficiency of grade NYHA III or IV)
• • 5. Severe neurological diseases
• • 6. Severe liver or kidney diseases
• • 7. Any acute or chronic disease that may put the donor at risk in case of cell donation by leukapheresis
• • 8. Malignant neoplasms, except in situ carcinoma after complete removal
• • 9. Known infections or exposures to human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis E virus, West Nile virus (WNV; testing only required during WNV season \[June 1st to November 30th of a year\]), gonorrhea or syphilis, with the risk of transmission of infection (Note: If tested positive for EBV immunoglobulin \[Ig\]M, an EBV PCR test has to be performed for confirmation)
• • 10. Active bacterial, mycotic or viral infection, except active infections that, in the investigator's opinion, do not affect patient safety (e.g., foot fungus, nail fungus, or common warts)
• • 11. Known malaria infection; known infection of tuberculosis, Q fever, Salmonella typhi and paratyphi, or osteomyelitis (if not medically documented to have been cured for 2 years); known toxoplasmosis (except if symptom free for 6 months); after completion of treatment for rheumatic fever (except if treatment was completed for 2 years)
• • 12. Known transmissible spongiform encephalopathies
• • 13. Known protozoonosis (babesiosis, trypanosomiasis \[e.g., chagas\], leishmaniosis), known chronic bacterial infections as brucellosis, rickettsiosis, leprosy, relapsing fever, melioidosis, tularemia (except after assured healing according to documented medical assessment)
• • 14. Autoimmune diseases requiring systemic immunosuppressive therapy
• • 15. Allergies requiring systemic immunosuppressive therapy
• • 16. Immunosuppressive therapy within 6 months prior screening
• • 17. Known or suspected abuse of alcohol, drugs, or medicinal products
• • 18. Unexplained night sweats, unexplained fever, unexplained weight loss, prolonged unexplained cough or diarrhea, unexplained skin lesions, lymph gland swelling or thrush
• • 19. Dura mater and/or cornea grafts, allogeneic organ transplants, xenotransplants, pituitary hormones of human origin received
• • 20. Stay of longer than 6 months in the United Kingdom between 1980 and 1996 and/or an operation and/or blood transfusion in the United Kingdom after 01-Jan-1980
• • 21. Operations or other invasive interventions (e.g., endoscopies, biopsies, catheter applications, acupunctures \[except acupuncture with sterile and/or disposable needles\]) within 4 months prior to Screening
• • 22. Any invasive exposure to blood (i.e., allogeneic blood components or plasma derivatives) or blood-contaminated injection needles or instruments, tattoos or piercings within 4 months prior to Screening
• • 23. Positive PCR test result for SARS-CoV-2 at Screening
• • 24. Hemoglobin \<8.0 g/dL, thrombocytes \<80,000/μL and/or leukocytes \<3,000/μL
• • 25. Known history of hypersensitivity to components used in the leukapheresis setting (i.e., components of the anticoagulant acid citrate dextrose solution)
• • 26. Any finding or medical condition prohibiting the inclusion in the trial according to the judgment of the responsible leukapheresis physician (including assessment of the suitability of the veins for leukapheresis by the investigator)
• Patients:
• • 1. Preexisting severe psychiatric disorder
• • 2. Heart insufficiency of grade NYHA III or IV
• • 3. Severe liver disease (aspartate aminotransferase or alanine aminotransferase or gamma glutamyl transpeptidase ≥3 x ULN)
• • 4. Active infection of HIV, HBV, HCV, EBV or syphilis
• • 5. Active bacterial, mycotic, or viral infection, except active infections that, in the investigator's opinion, do not affect patient safety (e.g., foot fungus, nail fungus, or common warts)
• • 6. Negative serological test result for antibodies specific for Epstein-Barr virus (EBV) antigens (Note: EBV negative patients can be included if the donor is confirmed EBV negative)
• • 7. Malignant disease within 2 years prior to Screening, except basal cell carcinomas of the skin and in situ carcinomas
• • 8. Immunosuppressive therapy (e.g., for the treatment of an auto-immune disease) within 6 months prior Screening
• • 9. Preexisting vasculitis or collagenosis
• • 10. Known presence of irregular antibodies in Coombs test
• • 11. Vaccination within 4 weeks prior to Screening
• • 12. Spleen removed
• • 13. Known or suspected abuse of alcohol, drugs, or medicinal products
• • 14. Pregnant or breastfeeding
• • 15. Female patients who have a child with the donor or were pregnant from the donor due to possible sensitization
• • 16. Known history of hypersensitivity to the cellular components or to any other constituent/excipient in the pharmaceutical formulation of MIC (e.g., components of the SSP+ buffer as electrolytes (sodium chloride, potassium chloride, magnesium), citrate and phosphate, traces of mitomycin C, human albumin, or EDTA)
• • 17. Any finding or medical condition prohibiting the inclusion in the trial according to the judgment of the investigator
• • 18. Participation in an interventional clinical trial within 30 days prior to Screening or in observation period of a competing study
• • 19. Employees of the sponsor, or employees or relatives of the investigator